Quris-AI Strengthens Its Position in Bio-AI with Nortis Acquisition
Quris-AI, an innovative Bio-AI company, has announced an exciting milestone with its acquisition of Nortis, which was previously known as Numa Biosciences. This strategic move aims to revolutionize the pharmaceutical drug development landscape by integrating advanced technologies into Quris-AI's existing platform.
Integration of Pioneering Kidney-on-Chip Technology
As part of the acquisition, Quris-AI will incorporate Nortis's cutting-edge Kidney-on-Chip technology. This technology has already been recognized for its potential by esteemed institutions, including the National Center for Advancing Translational Sciences, a part of the National Institutes of Health. By blending this technology with Quris-AI's advanced machine learning solutions, the company aims to enhance drug safety predictions significantly.
Improving Drug Safety Predictions
This integration is set to play a pivotal role in the drug development process. With Nortis’s models that set new benchmarks for in-vitro drug testing, Quris-AI will leverage its patented patient-on-chip system to forecast human reactions to drugs more accurately. This approach can lead to the early elimination of harmful drug candidates, ultimately improving the safety and efficacy of new drugs.
Commitment to Advancing Kidney Research
In addition to incorporating Nortis's technology, Quris-AI is dedicated to continuing the collaborations that Nortis has established with various research institutes and pharmaceutical companies. These partnerships will focus on advancing clinical research related to kidney diseases, which is essential for fostering a better understanding and treatment of such conditions.
The Future of Drug Development Through AI
Dr. Isaac Bentwich, the founder and CEO of Quris-AI, voiced his enthusiasm about this acquisition. He highlighted the synergy between Nortis’s robust scientific background and Quris-AI's innovative Bio-AI capabilities. With this collaboration, both organizations are poised to significantly advance the prediction of drug safety, particularly during the critical pre-clinical and clinical phases.
Transforming Clinical Trials with AI
Quris-AI’s clinical prediction platform is globally recognized as the first of its kind that focuses on ensuring drug safety, which is instrumental given that many drug candidates fail during clinical testing. The integration of AI into the drug development framework not only streamlines the trial process but also enhances the accuracy of outcomes, promising a substantial leap over traditional methods.
Company Overview: Quris-AI
Quris-AI stands as the world’s first Bio-AI platform dedicated to preemptively evaluating the safety of drug candidates through innovative technologies. With rigorous backing from distinguished biotech investors, the company's dual headquarters in Boston and Israel positions it at the forefront of medical research and artificial intelligence. Quris-AI's portfolio consists of numerous patents, which underpin its commitment to transforming healthcare.
Contact Information
For those interested in learning more about Quris-AI’s pioneering work and recent developments, the company is open to inquiries. Media contact Erica Camilo has shared her availability for further communications. Her details are as follows: Phone: +1.610.639.5644; Email: erica@connexacommunications.com.
Frequently Asked Questions
What is Quris-AI?
Quris-AI is a Bio-AI company focused on improving drug safety and development processes through advanced technology integration.
What technology is Nortis known for?
Nortis is recognized for its Kidney-on-Chip technology, which significantly enhances in-vitro drug testing capabilities.
How will this acquisition benefit drug development?
The acquisition will enable better accuracy in drug safety predictions, allowing harmful drug candidates to be eliminated earlier in the process.
Who is the CEO of Quris-AI?
The CEO of Quris-AI is Dr. Isaac Bentwich, who founded the company and leads its innovative initiatives.
Where is Quris-AI headquartered?
Quris-AI has dual headquarters located in Boston and Israel, which facilitates its global outreach and collaboration.
